We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.

Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses. If you'd like more information about what a clinical trial is and how it is conducted, please go to this section.

Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly. However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.

In addition, here you will find a list of clinical trials which are still running but are closed to recruitment. 

All the trials listed in this page have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - and to the UK MDS Forum  for their continuous work in updating this listing.

Learn more about the latest MDS research

MDS Clinical Trials

LI-1

  1. SUB-TYPE OF MDS: MDS with 10% or more bone marrow blasts and also acute myeloid leukaemia
  2. SEVERITY OF MDS: Intermediate –2 or High Risk
  3. NAME OF DRUG: AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Lenalidomide and other novel therapies that will become available throughout the course of the study. These are all target treatments that block various pathways in the proliferation or growth of leukaemia cells.
Read full story

CAMELLIA

  1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukemia that has returned after a period of improvement (relapsed) or have not responded to previous treatment (refractory).
  2. SEVERITY OF MDS: Higher Risk
  3. NAME OF DRUG: Anti-CD47 monoclonal antibody, Hu5F9-G4 (target therapy that blocks the growth of cancer cells)
Read full story

Eltrombopag for MDS patients

  1. SUB-TYPE OF MDS: MDS patients who are platelet transfusion dependent
  2. SEVERITY OF MDS: intermediate 1 & 2 or high risk
  3. NAME OF DRUG: Eltrombopag, Promacta™/Revolade™
Read full story

AML 19

  1. SUB-TYPE OF MDS: MDS with 10% bone marrow blasts OR more; also acute myeloid leukaemia
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Mylotarg, CPX-351 (a novel drug which combines two anti-cancer drugs – cytarabine and daunorubicin in a new formulation)
Read full story

AML 18

  1. SUB-TYPE OF MDS: MDS with 10% or more bone marrow blasts; also acute myeloid leukaemia
  2. SEVERITY OF MDS: Intermediate – 2 or High Risk
  3. NAME OF DRUG: Mylotarg, AC220 (a novel drug that blocks the action of a gene – FLT3, which is important in the growth of blood cells
Read full story

Free donations by shopping